CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题：Novel Cell and Immune Engagers in Optimizing Tumor- Specific Immunity Post-Autologous Transplantation in Multiple Myeloma.
Novel Cell and Immune Engagers in Optimizing Tumor- Specific Immunity Post-Autologous Transplantation in Multiple Myeloma.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
自体干细胞移植（ASCT）是多发性骨髓瘤（MM）治疗的重要组成部分。ASCT后的环境提供了一个独特的机会，通过增强T细胞和NK细胞反应来提高骨髓瘤特异性免疫。为MM开发的众多治疗手段，包括细胞疗法、树突状疫苗、双特异性抗体和IL-15激动剂，为提高肿瘤特异性免疫提供了机会。维持治疗，包括免疫调节药物、蛋白酶体抑制剂和daratumumab，通过调节免疫系统表现出显著的抗骨髓瘤反应。来那度胺促进抗肿瘤免疫微环境，而daratumumab可能潜在导致NK细胞自相残杀。因此，了解常用维持药物对肿瘤特异性免疫恢复的影响非常重要。在这篇综述中，我们着眼于当前和新兴的治疗手段及其在ASCT后免疫重建背景下的整合，以改善MM患者的临床反应。2021 American Society for Transplantation and Cellular Therapy。由Elsevier Inc.出版。
Autologous stem cell transplantation (ASCT) is an important component of treatment of multiple myeloma (MM). The post-ASCT setting offers a unique opportunity to increase myeloma specific immunity through enhancement of T and NK cell responses. The vast array of therapeutics being developed for MM, including cell-based therapies, dendritic vaccines, bispecific antibodies, and IL-15 agonists, provide the opportunity to increase tumor-specific immunity.
Maintenance therapies, including immunomodulatory drugs, proteasome inhibitors, and daratumumab, exhibit a significant anti-myeloma response by modulating the immune system. Lenalidomide promotes an antitumoral immune microenvironment, whereas daratumumab can potentially cause NK cell fratricide.
Thus, understanding the effects of commonly used maintenance drugs on the restoration of tumor specific immunity is important. In this review, we look at current and emerging therapeutics and their integration post-ASCT in the context of immune reconstitution to improve clinical responses in patients with MM. 2021 American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc.
MEMBER ACCOUNT
登录成功会直接打开下一页。
